Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

By sjmartinez • June 23, 2024

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis. Dermatol Ther (Heidelb). 2024 Jun 22. doi: 10.1007/s13555-024-01201-4. Epub ahead of print. PMID: 38907877.

Tags: apremilast, cumulative clinical benefit, Dermatology, deucravacitinib, Oral treatments, psoriasis, Publications, Small molecules

Diagnosis and management of anti-p200 pemphigoid: Perspectives of international dermatologists with expertise in immunobullous diseases

Kasperkiewicz M, Xu J, Thapa M, Culton DA, Curman P, Hashimoto T, Meijer JM, Patsatsi A, Tomayko MM, Lehman JS, Schmidt E. Diagnosis and management[...]

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]